ResMed Inc. (NYSE:RMD) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: September 28, 2016
Zacks Investment Research has downgraded ResMed Inc. (NYSE:RMD) to Sell in a statement released on 09/28/2016.
Having a price of $64.49, ResMed Inc. (NYSE:RMD) traded 0.25% higher on the day. With the last stock price up 4.03% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. RMD has recorded a 50-day average of $67.05 and a two hundred day average of $62.16. Trade Volume was down over the average, with 336,479 shares of RMD changing hands under the typical 959,227
Recent Performance Chart
ResMed Inc. has PE ratio of 25.97 with a one year low of $50.47 and a one year high of $70.90 and has a market capitalization of $0.
A total of 11 brokerages have issued a ratings update on ResMed Inc.. One brokerage rating the company a strong buy, four brokerages rating the company a buy, eight brokerages rating the company a hold, two brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $59.06.
General Company Details For ResMed Inc. (NYSE:RMD)
ResMed Inc. is a holding company. The Company, through its subsidiaries, designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Company develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories. The Company owns interest in Inova Labs Inc., a medical device company specializing in the development and commercialization of oxygen therapy products. The Company holds interest in Brightree LLC, a provider of business management and clinical software applications for the post-acute care industry. The Company's manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.